Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Did you mean emetine acid and sulfur and titanium dioxide?
Displaying drugs 801 - 825 of 15328 in total

Miltefosine

Miltefosine is a broad spectrum antimicrobial, anti-leishmanial, phospholipid drug that was originally developed in the 1980s as an anti-cancer agent. It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of leishmaniasis, a neglected tropical disease. It can be administered topically or orally and...
Approved
Investigational
Matched Description: … It is currently the only recognized oral agent used to treat visceral, cutaneous, and mucosal forms of ... It can be administered topically or orally and is only indicated in patients aged 12 years or older. ... first line treatment for free-living amebae (FLA) infections such as primary amebic meningoencephalitis and …
Matched Categories: … Agents Against Leishmaniasis and Trypanosomiasis ... Antiparasitic Products, Insecticides and Repellents …

Tafamidis

Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Iupac: … 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid …
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …

Linagliptin

Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding . Linagliptin was approved by...
Approved
Matched Description: … that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and …
Matched Categories: … Alimentary Tract and Metabolism ... metformin and linagliptin ... linagliptin and empagliflozin ... metformin, linagliptin and empagliflozin ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Sacituzumab govitecan

Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab govitecan, which combines a humanized anti-trophoblast cell-surface antigen 2...
Approved
Investigational
Matched Description: … Commission and Health Canada respectively. ... [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed ... [A193653] In November 2021 and July 20 2023, sacituzumab govitecan was also approved by the European …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Antithymocyte immunoglobulin (rabbit)

Rabbit anti-thymocyte globulin. Thymoglobulin is a polyclonal antibody that suppresses certain types of immune cells responsible for acute organ rejection in transplant patients. Thymoglobulin is a mixture of antibodies intended to bind to various cell surface antigens. The most common mode of action of Thymoglobulin is via selective depletion of...
Approved
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Antilymphocyte immunoglobulin (horse)

Equine anti-thymocyte globulin is composed of purified gamma globulin containing primarily IgG against human thymus lymphocytes. It is formed by inoculating a horse with an antigen (human thymoyctes) which then induces the horse immune system's B-lymphocytes to produce IgG immunoglobulins specific for that antigen. The result is polyclonal IgG that...
Approved
Investigational
Matched Description: … system proteins including lymphocyte surface proteins, granulocytes, platelets, bone marrow cells, and ... currently indicated for the suppression of the immune system to prevent renal transplant rejection and ... Induction of T cell apoptosis and resulting T-cell lymphopenia found in vivo is credited for its therapeutic …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Corticorelin ovine triflutate

Corticorelin, available commercially as corticorelin ovine triflutate (tradename Acthrel), is a synthetic form of the peptide human corticotropin-releasing hormone (hCRH), a potent stimulator of adrenocorticotropic hormone (ACTH) release from the anterior pituitary. Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the pituitary...
Approved
Matched Description: … Endogenous forms hCRH are involved in the stress response and its main function is stimulation of the ... If corticorelin injection results in an increase of plasma ACTH and cortisol, the patient is diagnosed ... However, if corticorelin injection does not result in an increase of plasma ACTH and cortisol, the patient …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …

Diiodohydroxyquinoline

Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be used in the treatment of amoebiasis. The exact mechanism of action is unknown. Iodoquinol is not currently available in any FDA-approved products.
Approved
Matched Description: … Diiodohydroxyquinoline, also known as uidoquinol and iodoquinol, is a quinoline derivative that can be …
Matched Categories: … Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …

Bezlotoxumab

Bezlotoxumab is a fully humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to Clostridium difficile toxin B and neutralizes its effects. First approved by the FDA on October 21, 2016, bezlotoxumab is used to reduce the recurrence of C. difficile infection. On November 22, 2016, the Committee for Medicinal Products...
Approved
Investigational
Matched Description: … humanized ImmunoglobulinG1 (IgG1) kappa monoclonal antibody that binds to _Clostridium difficile_ toxin B and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …

Emicizumab

Emicizumab is a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and it has the capacity to bind simultaneously to activated Factor IX and Factor X. The ability of Emicizumab to bind to all these three different factors allows it to overcome immunogenicity and unstable...
Approved
Investigational
Matched Description: … Ltd. and co-developed with Roche and Genentech.[L1015] ... it has the capacity to bind simultaneously to activated Factor IX and Factor X. ... a humanized recombinant monoclonal antibody that mimics the function of the coagulation Factor VIII and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Blood and Blood Forming Organs …

Sutimlimab

Cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (AIHA) in which autoantibodies directed against red blood cell surface antigens cause hemolysis at low (3-4°C) temperatures.[A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in the elderly.[A245159,L40114] In approximately 90% of cases,...
Approved
Investigational
Matched Description: … [A245154,L40114] This cold subtype accounts for approximately 15-25% of all AIHA and is more common in ... IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and ... is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Satralizumab

Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … [A218551] It received subsequent approvals in Switzerland and Japan,[A218551] and was approved for use ... interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and ... at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Human varicella-zoster immune globulin

Human varicella-zoster immune globulin is a solvent/detergent-treated sterile liquid preparation of purified human immune globulin G (IgG) containing antibodies to varicella zoster virus (anti-VZV). It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the...
Approved
Matched Description: … It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and ... VariZIG to reduce the disease severity in high-risk patients who lack evidence of immunity to varicella and …
Matched Categories: … Fluids and Secretions ... Amino Acids, Peptides, and Proteins …

Fluvoxamine

Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised...
Approved
Investigational
Matched Description: … It was launched in the US in December 1994 and in Japan in June 1999. ... Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised …
Matched Categories: … Metabolic Side Effects of Drugs and Substances …

Tildrakizumab

Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy...
Approved
Investigational
Matched Description: … The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults ... The approved recommended dosage of ILUMYA is a subcutaneous injection of 100 mg at Weeks 0, 4, and every ... The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257 …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Lorazepam

Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm.
Approved
Matched Description: … Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic ... [A957] It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepine hypnotics and sedatives ... Benzodiazepines and benzodiazepine derivatives …

Sunitinib

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. ... agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and ... These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …

Eculizumab

Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246] Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Mirvetuximab soravtansine

Mirvetuximab soravtansine-gynx (IMGN853) is an antibody-drug conjugate (ADC) formed by a monoclonal antibody (M9346A) that targets folate receptor alpha (FRα), covalently joined by a cleavable disulfide linker to the genotoxic compound DM4 (also known as soravtansine or ravtansine).[A254392,L43967] DM4 is conjugated to the antibody with a drug-to-antibody ratio of 3.5:1....
Approved
Investigational
Matched Description: … DM4 leads to cell-cycle arrest and apoptosis and is also able to diffuse into neighboring cells and induce ... [A254382] After an ADC/receptor complex is formed, mirvetuximab soravtansine-gynx is internalized, and ... the surface of epithelial tumor cells, characteristic of ovarian, endometrial, triple-negative breast and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …

Mifamurtide

Mifamurtide is an immunomodulator with antitumor activity via activation of macrophages and monocytes. Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP). MDP is a motif present in all gram-positive and...
Approved
Experimental
Matched Description: … receptors (NLRs) and toll-like receptors present in macrophages and monocytes. ... signalling molecules and activators such as nucleotide-binding and oligomerization domain (NOD)-like ... of bactericidal and tumoricidal effects [A31745]. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents …

Alprazolam

Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse...
Approved
Illicit
Investigational
Matched Description: … ketoconazole and itraconazole. ... Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders. ... [L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like …
Matched Categories: … Hypnotics and Sedatives ... Benzodiazepines and benzodiazepine derivatives …

Phenformin

A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290)
Approved
Investigational
Withdrawn
Matched Description: … A biguanide hypoglycemic agent with actions and uses similar to those of metformin. …
Matched Categories: … Alimentary Tract and Metabolism ... phenformin and sulfonylureas …

Lasofoxifene

Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as...
Approved
Investigational
Matched Description: … It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment ... non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ... It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal …
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System …

Tetradecyl hydrogen sulfate (ester)

Sodium tetradecyl sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose veins . Sodium tetradecyl sulfate has been widely used since the 1950s, and in...
Approved
Matched Iupac: … [(7-ethyl-2-methylundecan-4-yl)oxy]sulfonic acid …
Matched Description: … is also used in medicine as a blood vessel irritant and sclerosing agent for hemorrhoids and varicose ... sulfate is an anionic surface-active agent which is used for its wetting properties in the industry and ... Sodium tetradecyl sulfate has been widely used since the 1950s, and in 1978 the first successful report …

Nirsevimab

Nirsevimab (MEDI8897) is a recombinant human immunoglobulin G1 kappa (IgG1ĸ) monoclonal antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. It binds to the prefusion conformation of the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry...
Approved
Investigational
Matched Description: … neutralizes several RSV A and B strains. ... antibody used to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and ... the RSV F protein, a glycoprotein involved in the membrane fusion step of the viral entry process, and …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Immune Sera and Immunoglobulins …
Displaying drugs 801 - 825 of 15328 in total